Related Experiment Video
Updated: Jan 10, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Adjuvant-metal-ion-chelating PTEN mRNA with cell-membrane-coating augments the immune sensitivity for precise cancer
Mengyu Guo1, Jin-Cheng Guo2, Haodong Yao3
1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, New Cornerstone Science Laboratory, and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
Abstract:
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) messenger RNA (mRNA) delivery has fueled a great hope for tumor immunotherapy via augmenting the immune sensitivity in many human cancers. However, therapeutic efficacy and clinical translation are limited by inadequate mRNA expression, insufficient immune stimulation and stringent storage requirements. Herein, inspired by the intrinsic properties of metal ions and exosomes, we developed a biomimetic delivery system (Mn-NP@PM) with superior stability for precise colorectal cancer immunotherapy. This platform employs adjuvant-metal-ion chelation for PTEN mRNA loading and PD-L1 antibodies (αPD-L1)-modified monocyte-macrophage membrane coating for mRNA protection and tumor targeting. Mn2+ was specifically selected due to its capacity for reversible mRNA binding through weak non-electrostatic interactions, facilitating efficient release, while simultaneously activating the stimulator of interferon genes (STING) pathway. Importantly, Mn-NP@PM exhibited membrane fusion for immediate cytosolic mRNA delivery, bypassing endo-lysosomal escape, optimizing transportation efficiency. Clinical-data-driven analyses further demonstrated that Mn-NP@PM-mediated PTEN restoration significantly increased T-cell infiltration and strengthened antitumor immunity in humanized patient derived xenograft (PDX) models. Collectively, this biomimetic, metal-ion-chelating, membrane-coated mRNA delivery system represents a versatile and clinically translatable strategy for personalized cancer immunotherapy.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment